{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:15:25Z","timestamp":1793092525457,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177593","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:15:09Z","timestamp":1743869709000},"page":"177593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The protective effect of amylin in type 2 diabetes: Yes or no"],"prefix":"10.1016","volume":"996","author":[{"given":"Mansour","family":"Alanazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-Kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-8549","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177593_bib1","article-title":"Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats","volume":"146","author":"Abdelaziz","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.177593_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.febslet.2013.01.017","article-title":"Mechanisms of islet amyloidosis toxicity in type 2 diabetes","volume":"587","author":"Abedini","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2025.177593_bib3","doi-asserted-by":"crossref","first-page":"243a","DOI":"10.1016\/j.bpj.2011.11.1338","article-title":"Effects of heparin on amylin fibrillization","volume":"102","author":"Alexandrescu","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejphar.2025.177593_bib4","first-page":"44","article-title":"Hypoglycemia and Alzheimer disease risk: the possible role of dasiglucagon","author":"Ali","year":"2024","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177593_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102084","article-title":"The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation","volume":"91","author":"Al-kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177593_bib6","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1080\/15548627.2024.2367356","article-title":"Dysregulation of pancreatic \u03b2-cell autophagy and the risk of type 2 diabetes","volume":"20","author":"Al-kuraishy","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.ejphar.2025.177593_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22243","article-title":"Kynurenine pathway in type 2 diabetes: role of metformin","volume":"85","author":"Al-Qahtani","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejphar.2025.177593_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13098-023-01082-1","article-title":"The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases","volume":"15","author":"Alrouji","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2025.177593_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13098-023-01149-z","article-title":"Antidepressants and type 2 diabetes: highways to knowns and unknowns","volume":"15","author":"Alruwaili","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2025.177593_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170683","article-title":"Peptides in the regulation of glucagon secretion","volume":"148","author":"Andersen","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2025.177593_bib11","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1002\/anie.202000148","article-title":"The human host-defense peptide cathelicidin LL-37 is a nanomolar inhibitor of amyloid self-assembly of islet amyloid polypeptide (IAPP)","volume":"59","author":"Armiento","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejphar.2025.177593_bib12","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1111\/ejn.15376","article-title":"A selective role for receptor activity-modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body weight and food intake in male mice","volume":"54","author":"Arrigoni","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177593_bib13","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2009-2133","article-title":"Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?","volume":"95","author":"Asmar","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177593_bib14","doi-asserted-by":"crossref","first-page":"36621","DOI":"10.1074\/jbc.M006170200","article-title":"Degradation of amylin by insulin-degrading enzyme","volume":"275","author":"Bennett","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177593_bib15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/diabetes.52.9.2315","article-title":"An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures","volume":"52","author":"Bennett","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-161192","article-title":"The link between type 2 diabetes and neurodegeneration: roles for amyloid-\u03b2, amylin, and tau Proteins","volume":"59","author":"Bharadwaj","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2025.177593_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/molecules27031021","article-title":"Molecular mechanisms of amylin turnover, misfolding and toxicity in the pancreas","volume":"27","author":"Bhowmick","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.177593_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170366","article-title":"Amylin brain circuitry","volume":"132","author":"Boccia","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2025.177593_bib19","article-title":"Human islet amyloid polypeptide (hIAPP) protofibril-specific antibodies for detection and treatment of type 2 diabetes","volume":"9","author":"Bortoletto","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2025.177593_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2019.11.034","article-title":"Amylin and leptin interaction: role during pregnancy, lactation and neonatal development","volume":"447","author":"Boyle","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2025.177593_bib21","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.177593_bib22","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1038\/srep04267","article-title":"Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies","volume":"4","author":"Bram","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177593_bib23","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/ja1007867","article-title":"Role of zinc in human islet amyloid polypeptide aggregation","volume":"132","author":"Brender","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2025.177593_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00401050","article-title":"Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man","volume":"33","author":"Bretherton-Watt","year":"1990","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.177593_bib25","first-page":"1032","article-title":"Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man","volume":"74","author":"Bretherton-Watt","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177593_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.118971","article-title":"Human amylin aggregates release within exosomes as a protective mechanism in pancreatic \u03b2 cells: pancreatic \u03b2-hippocampal cell communication","volume":"1868","author":"Burillo","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"375","key":"10.1016\/j.ejphar.2025.177593_bib27","article-title":"A structural basis for amylin receptor phenotype","volume":"1979","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177593_bib28","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.2337\/db07-0178","article-title":"Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic \u03b2-cell apoptosis","volume":"56","author":"Casas","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00125-003-1304-4","article-title":"Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?","volume":"47","author":"Clark","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.177593_bib30","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1073\/pnas.85.20.7763","article-title":"Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle","volume":"85","author":"Cooper","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejphar.2025.177593_bib31","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejphar.2025.177593_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12974-023-02914-7","article-title":"Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging","volume":"20","author":"Corraliza-Gomez","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2025.177593_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7570\/jomes21071","article-title":"Amylin as a future obesity treatment","volume":"30","author":"Dehestani","year":"2021","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.ejphar.2025.177593_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.25668","article-title":"Amylin as a potential link between type 2 diabetes and Alzheimer disease","volume":"87","author":"Despa","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2025.177593_bib35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/0024-3205(92)90106-Y","article-title":"Amylin","volume":"51","author":"Edwards","year":"1992","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.177593_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1573399812666151020101222","article-title":"Pancreatic \u03b2-cells and type 2 diabetes development","volume":"13","author":"Elizabeth","year":"2015","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.ejphar.2025.177593_bib37","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177593_bib38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177593_bib39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41594-020-0496-3","article-title":"Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly","volume":"27","author":"Gallardo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.177593_bib40","first-page":"584","article-title":"Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like-peptide-1 (7-36)-amide (GLP-1)","volume":"39","author":"Gedulin","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.177593_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist","volume":"137","author":"Gedulin","year":"2006","journal-title":"AC187. Regul Pept."},{"key":"10.1016\/j.ejphar.2025.177593_bib42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.biopsych.2023.07.011","article-title":"Amylin modulates a ventral tegmental area\u2013to\u2013medial prefrontal cortex circuit to suppress food intake and impulsive food-directed behavior","volume":"95","author":"Geisler","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177593_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/13813455.2017.1308382","article-title":"Fasting levels of insulin and amylin after acute pancreatitis are associated with pro-inflammatory cytokines","volume":"123","author":"Gillies","year":"2017","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2025.177593_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5002305","article-title":"Amylin deposition in the kidney of patients with diabetic nephropathy","volume":"72","author":"Gong","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2025.177593_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1590\/S0001-37652013005000011","article-title":"Amylin induces hypoglycemia in mice","volume":"85","author":"Guerreiro","year":"2013","journal-title":"An. Acad. Bras. Cienc."},{"key":"10.1016\/j.ejphar.2025.177593_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89590","article-title":"\u03b2 Cell\u2013specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity","volume":"1","author":"Gurlo","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2025.177593_bib47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2353\/ajpath.2010.090532","article-title":"Evidence for proteotoxicity in \u03b2 cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway","volume":"176","author":"Gurlo","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2025.177593_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","article-title":"Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis","volume":"29","author":"Haataja","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2025.177593_bib49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.tjnut.2023.03.014","article-title":"Glycomacropeptide impacts amylin-mediated satiety, postprandial markers of glucose homeostasis, and the fecal microbiome in obese postmenopausal women","volume":"153","author":"Hansen","year":"2023","journal-title":"J. Nutr."},{"key":"10.1016\/j.ejphar.2025.177593_bib50","article-title":"In-vivo like studies of the h-IAPP amyloid precursors using dielectric relaxation spectroscopy","author":"Hirai","year":"2013","journal-title":"Worcester polytechnic institute"},{"key":"10.1016\/j.ejphar.2025.177593_bib51","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2025.177593_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.576192","article-title":"Connecting Alzheimer's disease with diabetes mellitus through amyloidogenic evolvability","volume":"12","author":"Ho","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2025.177593_bib53","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0002-9440(10)64852-3","article-title":"A feline model of experimentally induced islet amyloidosis","volume":"157","author":"Hoenig","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2025.177593_bib54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide,the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk","volume":"4","author":"Hoogwerf","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2025.177593_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-016-1022-9","article-title":"Human amylin proteotoxicity impairs protein biosynthesis, and alters major cellular signaling pathways in the heart, brain and liver of humanized diabetic rat model in vivo","volume":"12","author":"Ilaiwy","year":"2016","journal-title":"Metabolomics"},{"key":"10.1016\/j.ejphar.2025.177593_bib56","doi-asserted-by":"crossref","first-page":"10462","DOI":"10.1021\/acsami.8b19506","article-title":"Probing the aggregation and immune response of human islet amyloid polypeptides with ligand-stabilized gold nanoparticles","volume":"11","author":"Javed","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejphar.2025.177593_bib57","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-150379","article-title":"Impact of insulin degrading enzyme and neprilysin in Alzheimer's disease biology: characterization of putative cognates for therapeutic applications","volume":"48","author":"Jha","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2025.177593_bib58","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177593_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13340-018-0347-1","article-title":"IAPP\/amylin and \u03b2-cell failure: implication of the risk factors of type 2 diabetes","volume":"9","author":"Kanatsuka","year":"2018","journal-title":"Diabetol Int"},{"key":"10.1016\/j.ejphar.2025.177593_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2020.112958","article-title":"Distributed amylin receptor signaling and its influence on motivated behavior","volume":"222","author":"Kern","year":"2020","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2025.177593_bib61","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1111\/dom.15630","article-title":"Depression and type 2 diabetes: a causal relationship and mechanistic pathway","volume":"26","author":"Khawagi","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177593_bib62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/cells7080095","article-title":"Role and cytotoxicity of amylin and protection of pancreatic islet \u03b2-cells from amylin cytotoxicity","volume":"7","author":"Kiriyama","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177593_bib63","article-title":"Inhibition of human islet amyloid polypeptide aggregation in type 2 diabetes by Hsp70 molecular chaperones","volume":"vol. 2016","author":"Ladjimi","year":"2019"},{"key":"10.1016\/j.ejphar.2025.177593_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.177593_bib65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177593_bib66","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejphar.2025.177593_bib67","first-page":"1","article-title":"Combined amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177593_bib68","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2174\/1389203720666190328111833","article-title":"Human amylin: from pathology to physiology and pharmacology","volume":"20","author":"Ling","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ejphar.2025.177593_bib69","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S9::AID-DIA397>3.0.CO;2-D","article-title":"Amylin: history and overview","volume":"14","author":"Ludvik","year":"1997","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2025.177593_bib70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acschembio.8b01128","article-title":"Glycated insulin exacerbates the cytotoxicity of human islet amyloid polypeptides: a vicious cycle in type 2 diabetes","volume":"14","author":"Ma","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.177593_bib71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177593_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"MacK","year":"2010","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2025.177593_bib73","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/bi0621967","article-title":"Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology","volume":"46","author":"Marek","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2025.177593_bib74","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1530\/EJE-21-1261","article-title":"Therapy of endocrine disease: amylin and calcitonin\u2013 physiology and pharmacology","volume":"186","author":"Mathiesen","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177593_bib75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.physbeh.2016.02.034","article-title":"Amylin-mediated control of glycemia, energy balance, and cognition","volume":"162","author":"Mietlicki-Baase","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2025.177593_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31579\/2693-4779\/154","article-title":"Cagrilintide combined with semaglutide: a new approach for treatment of obesity and type 2 diabetes","volume":"8","author":"Mikhail","year":"2023","journal-title":"Clinical Research and clinical Trials"},{"key":"10.1016\/j.ejphar.2025.177593_bib77","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1021\/acs.chemrev.0c00981","article-title":"Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes","volume":"121","author":"Milardi","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.ejphar.2025.177593_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000199","article-title":"Aggregation propensity of the human proteome","volume":"4","author":"Monsellier","year":"2008","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejphar.2025.177593_bib79","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.peptides.2011.09.007","article-title":"Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state","volume":"32","author":"Moreno","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2025.177593_bib80","doi-asserted-by":"crossref","first-page":"E684","DOI":"10.1152\/ajpendo.2000.278.4.E684","article-title":"Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes","volume":"278","author":"Mulder","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177593_bib81","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12192-010-0204-z","article-title":"Increased serum HSP70 levels are associated with the duration of diabetes","volume":"15","author":"Nakhjavani","year":"2010","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ejphar.2025.177593_bib82","doi-asserted-by":"crossref","first-page":"17389","DOI":"10.1073\/pnas.2007136117","article-title":"Calpain inhibitor and ibudilast rescue \u03b2 cell functions in a cellular model of Wolfram syndrome","volume":"117","author":"Nguyen","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejphar.2025.177593_bib83","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1110\/ps.48702","article-title":"Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation","volume":"11","author":"Nilsson","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejphar.2025.177593_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152662","article-title":"Circulating differentially methylated amylin DNA as a biomarker of \u03b2-cell loss in type 1 diabetes","volume":"11","author":"Olsen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177593_bib85","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.metabol.2013.08.007","article-title":"\u03b2-Amyloid-induced cognitive dysfunction impairs glucose homeostasis by increasing insulin resistance and decreasing \u03b2-cell mass in non-diabetic and diabetic rats","volume":"62","author":"Park","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2025.177593_bib86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-180421","article-title":"Neuroprotective effects of the amylin analog, pramlintide, on Alzheimer's disease are associated with oxidative stress regulation mechanisms","volume":"69","author":"Patrick","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2025.177593_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02899719","article-title":"The genesis of apudamyloid in endocrine polypeptide tumours: histochemical distinction from immunamyloid","volume":"10","author":"Pearse","year":"1972","journal-title":"Virchows Archiv B Cell Pathology Zell-pathologie"},{"key":"10.1016\/j.ejphar.2025.177593_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116129","article-title":"Novel mechanisms involved in leptin sensitization in obesity","volume":"223","author":"Pena-Leon","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177593_bib89","first-page":"1","article-title":"DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue","author":"Petersen","year":"2024","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2025.177593_bib90","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.2337\/diabetes.50.2007.S160","article-title":"\u03b2-cell dysfunction and failure in type 2 diabetes: potential mechanisms","volume":"50","author":"Porte","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2025.177593_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.760914","article-title":"The role of the human hypothalamus in food intake networks: an MRI perspective","volume":"8","author":"Roger","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ejphar.2025.177593_bib93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","article-title":"GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities","volume":"166","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177593_bib94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/ijpvm.IJPVM_425_20","article-title":"Pramlintide: an amylin analogue protects endothelial cells against oxidative stress through regulating oxidative markers and NF-\u03bab expression","volume":"13","author":"Safaeian","year":"2022","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.ejphar.2025.177593_bib95","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0002-9440(10)64848-1","article-title":"S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin","volume":"157","author":"Sakagashira","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2025.177593_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00500385","article-title":"Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients","volume":"34","author":"Sanke","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.177593_bib97","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib98","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1021\/acschemneuro.0c00588","article-title":"Lipid-chaperone hypothesis: a common molecular mechanism of membrane disruption by intrinsically disordered proteins","volume":"11","author":"Sciacca","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177593_bib99","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":"Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177593_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.ejphar.2025.177593_bib101","doi-asserted-by":"crossref","first-page":"40857","DOI":"10.1074\/jbc.M111.232801","article-title":"Involvement of ATP-sensitive potassium (K ATP) channels in the loss of beta-cell function induced by human islet amyloid polypeptide","volume":"286","author":"Soty","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177593_bib102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.ejphar.2025.177593_bib103","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1507\/endocrj.K09E-051","article-title":"Role of copper ion in the pathogenesis of type 2 diabetes","volume":"56","author":"Tanaka","year":"2009","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejphar.2025.177593_bib104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/protein\/gzz041","article-title":"Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice","volume":"32","author":"Templin","year":"2019","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ejphar.2025.177593_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109983","article-title":"Effect of empagliflozin on plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with type 2 diabetes","volume":"190","author":"Tric\u00f2","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.177593_bib106","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2337\/diabetes.50.3.534","article-title":"The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site","volume":"50","author":"Wang","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/JCMA.0000000000000602","article-title":"Change of plasma amylin after bariatric surgery challenged by oral glucose is associated with remission of type 2 diabetes mellitus","volume":"84","author":"Wang","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.ejphar.2025.177593_bib108","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diab.42.2.330","article-title":"Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets","volume":"42","author":"Wang","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177593_bib109","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1111\/dom.15270","article-title":"Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets","volume":"25","author":"Wen","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177593_bib110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0006-291X(86)90708-4","article-title":"A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas","volume":"140","author":"Westermark","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.177593_bib111","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.1074\/jbc.M115.712455","article-title":"Differential activation of innate immune pathways by distinct islet amyloid polypeptide (IAPP) aggregates","volume":"291","author":"Westwell-Roper","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177593_bib112","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s001250050088","article-title":"Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans","volume":"37","author":"Wilding","year":"1994","journal-title":"Diabetologia: Clinical and Experimental Diabetes and Metabolism"},{"key":"10.1016\/j.ejphar.2025.177593_bib113","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/EC9.0000000000000029","article-title":"Amylin: new insight into pathogenesis, diagnosis, and prognosis of non-insulin-dependent diabetes-mellitus-related cardiomyopathy","volume":"2","author":"Xie","year":"2022","journal-title":"Emergency and Critical Care Medicine"},{"key":"10.1016\/j.ejphar.2025.177593_bib114","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejphar.2025.177593_bib115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4239\/wjd.v7.i9.189","article-title":"Neuroendocrine hormone amylin in diabetes","volume":"7","author":"Zhang","year":"2016","journal-title":"World J. Diabetes"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:28:03Z","timestamp":1762144083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925003474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":115,"alternative-id":["S0014299925003474"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177593","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The protective effect of amylin in type 2 diabetes: Yes or no","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177593"}}